BrainStorm receives $15.9M CIRM grant

The California Institute for Regenerative Medicine (CIRM) awarded BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) $15.9 million to fund a Phase III trial of NurOwn to treat amyotrophic lateral sclerosis. BrainStorm said it is in "advanced stages" of planning the trial, which is to enroll about 200 patients with faster-progressing disease...